Brief: HKEX Censures Jilin Province Huinan Changlong Bio-Pharmacy
13/06/2023 11:30
June 13 (Reuters) - HKEX:
* CENSURES JILIN PROVINCE HUINAN CHANGLONG BIO-PHARMACY
* IMPOSES DIRECTOR UNSUITABILITY STATEMENT AGAINST FORMER
INDEPENDENT NON-EXECUTIVE DIRECTOR OF JILIN PROVINCE HUINAN
CHANGLONG BIO-PHARMACY
Source text for Eikon: ID:nHKS9PVbNP
Further company coverage: 8049.HK
((reuters.briefs@thomsonreuters.com;))
Recent news on Jilin Province Huinan Changlong Bio-pharmacy
See all newsJilin Changlong Bio-pharmacy interim profit rises on lower costs
Brief: Jilin Province Huinan Changlong Bio-pharmacy Posts H1 Revenue Of RMB 435 million
Brief: Jilin Province Huinan Changlong Bio-Pharmacy Profit For Year Attributable Rmb198.9 Million
Brief: Jilin Province Huinan Changlong Bio-Pharmacy Subscribes To ICBC Structured Deposit Product
Brief: Jilin Province Huinan Changlong Bio-Pharmacy Subscribes To ICBC Wealth Management Product For RMB50 MLN